+Compare
ALEC
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
417.32M

ALEC Price Prediction, Alector AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ALEC with price predictions
07:00 PM EST Nov 30, 2023

ALEC's RSI Indicator recovers from oversold territory

The RSI Oscillator for ALEC moved out of oversold territory on November 14, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In of the 25 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on ALEC as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALEC just turned positive on November 21, 2023. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

ALEC moved above its 50-day moving average on December 01, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALEC entered a downward trend on November 22, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.567) is normal, around the industry mean (20.645). P/E Ratio (14.327) is within average values for comparable stocks, (137.274). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (4.292) is also within normal values, averaging (329.009).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ALEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I. Advisor
published Earnings

ALEC is expected to report earnings to rise 47.75% to -78 cents per share on March 26

Alector ALEC Stock Earnings Reports
Q4'23
Est.
$-0.78
Q3'23
Beat
by $0.13
Q2'23
Beat
by $0.84
Q1'23
Beat
by $0.21
Q4'22
Missed
by $0.17
The last earnings report on November 07 showed earnings per share of -52 cents, beating the estimate of -66 cents. With 378.49K shares outstanding, the current market capitalization sits at 417.32M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 27%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 173%. For the same stocks of the Industry, the average monthly volume growth was -7% and the average quarterly volume growth was 52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
131 Oyster Point Boulevard
Phone
+1 415 231-5660
Employees
273
Web
https://www.alector.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTHFX39.870.96
+2.47%
Fuller & Thaler Behavioral Sm-Cp Eq R6
GISOX16.670.17
+1.03%
Grandeur Peak Intl Stalwarts Inv
MNBWX18.31N/A
N/A
Manning & Napier Pro-Blend Extnd Term W
DPUYX18.44N/A
N/A
BNY Mellon US Equity Y
MLMAX16.26N/A
N/A
Morgan Stanley Instl Global Core A

ALEC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALEC has been loosely correlated with DNLI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ALEC jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALEC
1D Price
Change %
ALEC100%
+2.95%
DNLI - ALEC
48%
Loosely correlated
+2.43%
XNCR - ALEC
46%
Loosely correlated
+2.56%
NRIX - ALEC
45%
Loosely correlated
+10.93%
VERV - ALEC
44%
Loosely correlated
+4.48%
AGEN - ALEC
43%
Loosely correlated
+0.72%
More